Research Progress of Osimertinib Supported by Nanodrug Delivery System Against Non-small Cell Lung Cancer

VernacularTitle:纳米递药系统负载奥希替尼抗非小细胞肺癌的研究进展
Author: Rugui LIU ¹ ; Ruirui ZHAO ; Chunzhao LIU ; Xiao WU
Author Information

1. Medical Science Center of Qingdao University, Qingdao 266075, China
Publication Type:Research Article
Keywords: NSCLC; Osimertinib; Nanodrug delivery system
From: Cancer Research on Prevention and Treatment 2024;51(2):134-139
CountryChina
Language:Chinese
Abstract: Osimertinib is an irreversible third representative epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC) with T790M resistance and classical EGFR mutations. However, the therapeutic effectiveness of osimertinib is limited by acquired drug-resistance, poor water solubility and low tumor accumulation rates. Nanodrug delivery systems can increase the solubility and stability of drugs, prolong the blood circulation time of drugs, improve the uptake rate of cells, promote drug accumulation in tumor tissues, and improve drug resistance. Thus, they are effective in overcoming the limitations of traditional targeted drugs. In this study, we reviewed the mechanism of action of the third-generation EGFR-TKI osimertinib, focused on research advances in osimertinib nanodrug delivery systems against NSCLC, and explored the challenges and future development direction in this field.